{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:40:11Z","timestamp":1790872811516,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.transproceed.2023.11.021","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T09:13:57Z","timestamp":1704791637000},"page":"105-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Low-Dose vs Standard-Dose Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplantation: A Single-Center Retrospective Analysis"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6570-2690","authenticated-orcid":false,"given":"Katalin","family":"Farkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabella","family":"Dinnyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Rem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Telkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Remport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Piros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Szijarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Huszty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2023.11.021_bib0001","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0002","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.transproceed.2011.03.067","article-title":"Cytomegalovirus seroprevalence among solid organ donors in Hungary: correlations with age, gender, and blood group","volume":"43","author":"Varga","year":"2011","journal-title":"Transpl P"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0003","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.10.1.86","article-title":"Infections in solid-organ transplant recipients","volume":"10","author":"Patel","year":"1997","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 7","key":"10.1016\/j.transproceed.2023.11.021_bib0004","doi-asserted-by":"crossref","first-page":"S754","DOI":"10.1093\/clinids\/12.Supplement_7.S754","article-title":"Impact of cytomegalovirus infection on organ transplant recipients","volume":"12","author":"Rubin","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0005","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1399-0012.2010.01208.x","article-title":"The impact of cytomegalovirus infection >\/=1 year after primary renal transplantation","volume":"24","author":"Browne","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0006","first-page":"515","article-title":"Cytomegalovirus infection after kidney transplantation and long-term graft loss","volume":"37","author":"Lopez-Oliva","year":"2017","journal-title":"Nefrologia"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0007","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eimc.2009.07.008","article-title":"Direct and indirect effects of cytomegalovirus: can we prevent them?","volume":"28","author":"Razonable","year":"2010","journal-title":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12879-018-3493-y","article-title":"Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared with high-dose valacyclovir: a parallel group, open-label, randomized controlled trial","volume":"18","author":"Reischig","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0010","first-page":"774","article-title":"Early clinical manifestations and laboratory findings before and after treatment of cytomegalovirus infection in kidney transplant patients","volume":"28","author":"Siddiqui","year":"2017","journal-title":"Saudi J Kidney Dis Transplant Saudi Arabia"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0012","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1157\/13114394","article-title":"Indirect effects of cytomegalovirus infection in solid organ transplant recipients","volume":"26","author":"Perez-Sola","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0013","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.transproceed.2023.11.021_bib0014","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1111\/j.1432-2277.1994.tb01385.x","article-title":"Positive donor and negative recipient cytomegalovirus status is a detrimental factor for long-term renal allograft survival","volume":"7","author":"Petersen","year":"1994","journal-title":"Transplant Int"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0015","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2011.03674.x","article-title":"Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials","volume":"11","author":"Brennan","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0016","doi-asserted-by":"crossref","first-page":"412","DOI":"10.12659\/AOT.915885","article-title":"Infectious complications of induction therapies in kidney transplantation","volume":"24","author":"Bayraktar","year":"2019","journal-title":"Ann Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0017","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ebiom.2018.07.032","article-title":"Negative impact of CMV and BKV infections on kidney-allograft function at 1-year post-transplantation: can it be changed by modifying immunosuppression?","volume":"34","author":"Malvezzi","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0018","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1592\/phco.24.14.1323.43152","article-title":"Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis","volume":"24","author":"Gabardi","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0019","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1469-0691.2005.01190.x","article-title":"The impact of early cytomegalovirus infection and disease in renal transplant recipients","volume":"11","author":"Sagedal","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0020","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1086\/319225","article-title":"Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients","volume":"32","author":"Singh","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0021","first-page":"293","article-title":"[Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir]","volume":"28","author":"Guirado","year":"2008","journal-title":"Nefrologia"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0022","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.2146\/ajhp060378","article-title":"Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy","volume":"63","author":"Baillie","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0023","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0024","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0026","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0027","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0028","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.transproceed.2008.02.048","article-title":"Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil","volume":"40","author":"Brum","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0029","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transproceed.2012.04.036","article-title":"Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+\/R- kidney transplant patients receiving thymoglobulin induction","volume":"45","author":"Luan","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0030","first-page":"526","article-title":"Efficacy and safety of low-dose versus standard-dose valganciclovir for prevention of cytomegalovirus disease in intermediate-risk kidney transplant recipients","volume":"14","author":"Halim","year":"2016","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0031","doi-asserted-by":"crossref","first-page":"168","DOI":"10.18433\/J3805B","article-title":"Effectiveness of valganciclovir 900mg versus 450mg for cytomegalovirus prophylaxis in renal transplantation: a systematic review and meta-analysis","volume":"20","author":"Xin","year":"2017","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0032","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/TP.0000000000000570","article-title":"Evaluation of low- versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients","volume":"99","author":"Gabardi","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0033","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.tp.0000251371.34968.ca","article-title":"Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants","volume":"83","author":"Weng","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0034","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ckj\/sfx145","article-title":"High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation","volume":"11","author":"Rissling","year":"2018","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.transproceed.2023.11.021_bib0035","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12780","article-title":"Low-dose valganciclovir prophylaxis for cytomegalovirus in intermediate-risk (R+) renal transplant recipients: single-center experience","volume":"19","author":"Khan","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0036","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jinf.2008.06.016","article-title":"Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation","volume":"57","author":"Avidan","year":"2008","journal-title":"J Infect"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0037","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.transproceed.2017.10.004","article-title":"Prolonged low-dose prophylaxis with valganciclovir in cytomegalovirus-negative recipients of kidney transplants from cytomegalovirus-positive donors allows seroconversion and prevents cytomegalovirus disease","volume":"49","author":"Halleck","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0038","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.transproceed.2017.12.025","article-title":"Prevention of late-onset cytomegalovirus infection and disease in donor-positive\/recipient-negative kidney transplant recipients using low-dose valganciclovir","volume":"50","author":"Nanmoku","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0039","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/ijot.ijot_84_20","article-title":"Evaluation of alternate-day valganciclovir prophylaxis for cytomegalovirus disease prevention in moderate risk renal transplant patients: a retrospective observational study","volume":"15","author":"Bhuwania","year":"2021","journal-title":"Indian J Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0040","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/cid\/ciq145","article-title":"Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: is less really more?","volume":"52","author":"Avery","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0041","first-page":"156","article-title":"Successful cost-effective prevention of cytomegalovirus disease in kidney transplant recipients using low-dose valganciclovir","volume":"15","author":"Gheith","year":"2017","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0042","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/15269248211046037","article-title":"Low-dose valganciclovir prophylaxis is safe and cost-saving in CMV-seropositive kidney transplant recipients","volume":"31","author":"Shi","year":"2021","journal-title":"Progr Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0043","first-page":"676","article-title":"Efficacy and safety of a lower-dose valganciclovir (valcyte) regimen for cytomegalovirus prophylaxis in kidney and pancreas transplant recipients","volume":"35","author":"Bhat","year":"2010","journal-title":"P T"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0044","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/00007890-198912000-00019","article-title":"Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation\u2013a report of 130 consecutive patients","volume":"48","author":"van den Berg","year":"1989","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0045","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1128\/JCM.41.7.3167-3174.2003","article-title":"Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation","volume":"41","author":"Pang","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0046","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1600-6143.2008.02220.x","article-title":"Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients","volume":"8","author":"Chamberlain","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0047","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1399-0012.2009.01205.x","article-title":"Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study","volume":"24","author":"Manuel","year":"2010","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0048","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1097\/TP.0000000000000570","article-title":"Evaluation of low- versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients","volume":"99","author":"Gabardi","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0049","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13104-017-2532-x","article-title":"Very-late-onset cytomegalovirus disease: a case-report and review of the literature","volume":"10","author":"Burgan","year":"2017","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0050","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1086\/427506","article-title":"Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence","volume":"40","author":"Singh","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0051","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1086\/324516","article-title":"Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir","volume":"184","author":"Razonable","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0052","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.TP.0000110408.83054.88","article-title":"Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review","volume":"77","author":"Butler","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-000-0086-0","article-title":"Poor compliance: the hidden risk factor","volume":"2","author":"LaRosa","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0054","first-page":"1421","article-title":"Factors affecting patient compliance with antihyperlipidemic medications in an HMO population","volume":"4","author":"Sung","year":"1998","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000453555","article-title":"Adherence in kidney transplant recipients","volume":"45","author":"Cukor","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0056","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/2010105815611811","article-title":"Resistant cytomegalovirus infection in renal transplant recipients","volume":"24","author":"Cherng","year":"2015","journal-title":"Proc Singap Healthc"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0057","first-page":"805","article-title":"Incidence of canciclovir resistance in CMV-positive renal transplant recipients and its association with UL97 gene mutations","volume":"16","author":"Aslani","year":"2017","journal-title":"Iran J Pharm Res"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0058","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/342385","article-title":"Ganciclovir-resistant cytomegalovirus in organ transplant recipients","volume":"35","author":"Limaye","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0059","article-title":"Suppression of CMV infection with letermovir in a kidney transplant patient","volume":"7","author":"Koepf","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0060","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/cid\/ciq143","article-title":"Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis","volume":"52","author":"Kalil","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2023.11.021_bib0061","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1128\/JCM.38.6.2122-2127.2000","article-title":"Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients","volume":"38","author":"Caliendo","year":"2000","journal-title":"J Clin Microbiol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134523007832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134523007832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:45:55Z","timestamp":1758577555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134523007832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0041134523007832"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.11.021","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose vs Standard-Dose Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplantation: A Single-Center Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}